The CORE (Center for Outcomes Research) Diabetes Model is an Internet-based, interactive computer model that determines the long-term health outcomes and economic consequences of implementing different treatment policies or interventions in type 1 and type 2 diabetes mellitus. This model is based on other sub-models that simulate medical complications related to diabetes, such as: cardiovascular disease, retinopathy, hypoglycaemia, nephropathy, neuropathy, foot ulcers, amputation, stroke, ketoacidosis, lactic acidosis and ultimately mortality. The model was introduced several years ago (I believe in 2004 by researchers in Switzerland) and has been used by some to support clinical and reimbursement decision-making. In the world of pharmacoeconomics, these types of models can be invaluable, as long as they are valid and reliable.
The CORE Diabetes Model has been validated against epidemiological and clinical studies. It provides an accurate representation of patient outcomes when compared to 66 studies of diabetes and its complications. Furthermore, its flexibility ensures that it can be used to compare diabetes management strategies across a variety of clinical settings.
In 2006, a new model emerged. The Economic Assessment of Glycemic Control and Long-Term Effects of diabetes (EAGLE) model was developed by researchers in Germany. Are we making the most out of these resources? I don't hear too many people talking about the use of computer-based modeling to reform healthcare. Do we really understand the pharmacoeconomics behind various diabetes therapies? Technology advocates know that these types of health economics models can be very useful in predicting long-term outcomes and economic consequences. My hope is that more companies will develop, validate, and implement such models for other chronic conditions as we prepare to make significant changes to our nation's healthcare system. Image source: Wellsphere
No comments:
Post a Comment